Summary
The pharmacokinetic behavior of navelbine was investigated in 19 patients presenting with advanced cancers (mainly women with breast cancer). Navelbine was given orally at seven dose levels of up to 200 mg/week. For a given dose, patients received four successive weekly treatments. Five subjects also received two different doses. After drug administration, plasma was collected for 48 or 72 h and monitored for navelbine concentration by radioimmunoassay. Absorption of navelbine was very rapid after oral administration: maximal drug concentrations were reached within the first 1 or 2 h (T max, 0.9–1.75 h;c max, 70.9–832.6 ng/ml), with absorption constants ranging from 0.85 to 2.42 l/h. A comparison of dose-normalised plasma concentration profiles revealed significant time dependence in six evaluable patients (P<0.001). Only four subjects who received low doses (≤100 mg/week) exhibited time-independent kinetics. All of the five patients who were treated at different doses displayed apparent dose dependence (P<0.001). No individual profile was characterised by both time- and dose-independent pharmacokinetics. In all, 18 patients presented biphasic plasma concentration-decay patterns, and only 1 subject exhibited monophasic decay kinetics. The navelbine pharmacokinetic parameters obtained following oral administration were similar to those observed after i. v. bolus injection and were characterised by high oral clearance (0.43–1.45 l h−1 kg−1), a large apparent volume of distribution (27.4–45.9 l/kg), and a long terminal half-life (24.2–56.5 h). Large intra- and inter-individual variations in pharmacokinetic parameters were observed. Moreover, after a high dose of 200 mg, an enterohepatic cycle and/or a delay in navelbine's absorption at a distal intestinal site as evidenced by a marked plasma level rebound was observed.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
References
Armand JP, Marty M (1989) Navelbine: a new step in cancer therapy. Semin Oncol 16(2) [Suppl 4]: 41–45
Boré P, Rahmani R, Cantfort JV, Focan C, Cano JP (1989) Pharmacokinetics of a new anticancer drug, navelbine, in patients: comparative study of radioimmunologic and radioactive determination methods. Cancer Chemother Pharmacol 23: 247–251
Favre R, Garnier G, Depierre A, Samak R, Cano JP, Carcassonne Y (1985) A phase I study of navelbine. In: Ishigami J (ed) Recent advances in chemotherapy. Anticancer section. University of Tokyo Press, Tokyo, pp 641–642
Hodes ME, Rohn RJ, Bond WH, Yardley J (1961) Vinca-leukoblastine: III. Clinical trial with the oral preparation. Cancer Chemother Rep 14: 129–133
Iliadis A (1985) APIS: a computer program for clinical pharmacokinetics. J Pharm Clin 4: 573–577
Iliadis A, Bruno R, Cano JP (1986) Steady-state dosage regimen calculations in linear pharmacokinetics. Int J Biomed Comput 18: 167–182
Jackson DV, Sethi VS, Spurr CL, White DR, Richard FI, Stuart JJ, Muss HB, Cooper MR, Castle MC (1981) Pharmacokinetics of vincristine infusion. Cancer Treat Rep 65: 1043–1048
Jackson DV, Sethi VS, Long TR, Muss HB, Spurr CL (1984) Pharmacokinetics of vindesine bolus and infusion. Cancer Chemother Pharmacol 13: 114–119
Lu K, Yap HY, Loo TL (1983) Clinical pharmacokinetics of vinblastine by continuous intravenous infusion. Cancer Res 43: 1405–1408
Mangeney P, Andriamialisoa RZ, Lallemand JY, Langlois N, Langlois Y, Potier P (1979) 5′-Noranhydrovinblastine. Prototype of new class of vinblastine derivatives. Tetrahedron 35: 2175–2179
Mangeney P, Andriamilisoa RZ, Langlois N, Langlois Y, Potier P (1979) A new class of antitumor compounds: 5′-nor and 5′,6′-secoderivatives of vinblastine-type alkaloids. J Org Chem 44: 3765–3768
Maral R, Bourut C, Chenu E, Mathé G (1981) Experimental in vivo cross-resistance of vinca alkaloid drugs. Cancer Chemother Pharmacol 5: 197–199
Maral R, Bourut C, Chenu E, Mathé G (1984) Experimental antitumor activity of 5′-noranhydrovinblastine, navelbine. Cancer Lett 22: 49–54
Nelson RL (1982) The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Med Pediatr Oncol 10: 115–127
Ohnuma T, Norton L, Andrejczak A, Holland JF (1985) Pharmacokinetics of vindesine given as an intravenous bolus and 24-h infusion in humans. Cancer Res 45: 464–469
Rahmani R, Kleisbauer JP, Cano JP, Martin M, Barbet J (1985) Clinical pharmacokinetics of vindesine infusion. Cancer Treat Rep 69: 839–844
Rahmani R, Martin M, Favre R, Cano JP, Barbet J (1985) Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections. Eur J Cancer Clin Oncol 2: 1409–1417
Rahmani R, Gueritte F, Martin M, Just S, Cano JP, Barbet J (1986) Comparative pharmacokinetics of antitumor vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to patients and rats. Cancer Chemother Pharmacol 16: 223–228
Rahmani R, Martin M, Barbet J, Cano JP (1986) Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5′-noranhydrovinblastine (navelbine). Cancer Res 44: 5609–5613
Rahmani R, Bruno R, Iliadis A, Favre R, Just S, Barbet J, Cano JP (1987) Clinical pharmacokinetics of the antitumor drug navelbine (5′-noranhydrovinblastine). Cancer Res 47: 5796–5799
Ratain MJ, Vogelzang NJ (1986) Phase I and pharmacologic study of vinblastine by prolonged continous infusion. Cancer Res 46: 4827–4830
Ratain MJ, Vogelzang NJ, Sinkule JA (1987) Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther 41: 61–67
Ribaud P, Gouveia J, Maral R, Potier P, Jasmin C, Mathé G (1981) Phase I study of 5′-noranhydrovinblastine (navelbine, NVB). Proc Am Assoc Cancer Res 22: 368
Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG (1982) The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 8: 215–219
Young JA, Howell SB, Green MR (1984) Pharmacokinetics of five-day continuous infusion of vinblastine. Cancer Chemother Pharmacol 12: 43–45
Author information
Authors and Affiliations
Additional information
Supported by institutional grants from the Institut National de la Santé et de Recherche Médicale, the Association pour la Recherche sur le Cancer, and P. F. Médicament
Rights and permissions
About this article
Cite this article
Zhou, X.J., Boré, P., Monjanel, S. et al. Pharmacokinetics of navelbine after oral administration in cancer patients. Cancer Chemother. Pharmacol. 29, 66–70 (1991). https://doi.org/10.1007/BF00686338
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686338